Fundraising FoxAGH Therapeutics
Nashville, US · Founded 2014 · Tennessee corporation
Find your way into AGH Therapeutics
Founders & leadership
MA
Matthew A GondaExecutiveMatthew A Gonda is an executive at AGH Therapeutics with prior experience in pharmaceutical and biotech R&D management, venture capital, and biomedical research. He has led drug development programs spanning early discovery through clinical stages and has worked with teams across gene therapy, vaccines, and small molecule therapeutics.
Board
RP
Raymond PirtleBoard director
TG
Thomas G AndrewsBoard director
JM
Jerry M KluftBoard director
LG
Lawrence GreerBoard director
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 3 of 4 rounds · 2015–2023
▶$725KraisedJan 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$725KraisedJan 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew GondaDirector
- Lawrence GreerDirector
- Satish JoshiDirector
- Michael HowellDirector
- Dennis CarloDirector
- Raymond PirtleDirector
- Offering amount
- $6M
- Amount sold
- $725K
- Minimum investment
- $50K
- First sale
- Dec 2023
- Incorporated
- Corporation, Tennessee
- Federal exemptions
- 06b
▶$3.6MraisedAug 2020 · 34 investors · Other Health CareRule 506(b)
▶$3.6MraisedAug 2020 · 34 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel PirtleDirector
- Thomas AndrewsDirector
- Daniel CanaleDirector
- Dennis CarloDirector
- Larry GreerDirector
- Matthew GondaExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $3.6M
- Minimum investment
- $25K
- Proceeds to insiders
- $383.1K
- First sale
- Jan 2020
- Incorporated
- Corporation, Tennessee, 2017
- Federal exemptions
- 06b
▶$2.1MofferedSep 2017 · PharmaceuticalsRule 506(b)
▶$2.1MofferedSep 2017 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis J CarloDirector
- Lawrence W GreerDirector
- Raymond PirtleDirector
- Matthew A GondaExecutive Officer, Director
- Thomas G AndrewsDirector
- Offering amount
- $2.1M
- Minimum investment
- $25K
- First sale
- Jul 2017
- Incorporated
- Corporation, Tennessee, 2014
- Federal exemptions
- 06b
▶$600KraisedJul 2016 · 7 investors · PharmaceuticalsRule 506(b)
▶$600KraisedJul 2016 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew A GondaExecutive Officer, Director
- Raymond PirtleDirector
- Thomas G AndrewsDirector
- Jerry M KluftDirector
- Lawrence GreerDirector
- Offering amount
- $4.5M
- Amount sold
- $600K
- Minimum investment
- $25K
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has AGH Therapeutics raised?
- AGH Therapeutics has disclosed $4.9M raised across 3 of its 4 known rounds.
- Where is AGH Therapeutics headquartered?
- AGH Therapeutics is headquartered in Nashville, US.